US 12,203,138 B2
Method to identify subjects at higher risk to develop an autoimmune disease based on genetic and/or phenotypic screening for epistatic variants in DDX39B (RS2523506) and IL7R (RS6897932)
Mariano A. Garcia-Blanco, Galveston, TX (US); Gaddiel Galarza-Munoz, Galveston, TX (US); Simon G. Gregory, Durham, NC (US); Farren B. S. Briggs, Cleveland Heights, OH (US); Lisa F. Barcellos, El Cerrito, CA (US); Shelton S. Bradrick, Galveston, TX (US); Irina Evsyukova, Cedar Grove, NC (US); and Dennis C. Ko, Durham, NC (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US); Duke University, Durham, NC (US); Case Western Reserve, Cleveland, OH (US); and The Regents of the University of California, Oakland, CA (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Feb. 23, 2021, as Appl. No. 17/182,846.
Application 17/182,846 is a division of application No. 15/928,939, filed on Mar. 22, 2018, granted, now 10,961,581.
Claims priority of provisional application 62/474,951, filed on Mar. 22, 2017.
Prior Publication US 2021/0180133 A1, Jun. 17, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/34 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6883 (2018.01); C12Q 1/683 (2018.01); C12Q 1/6851 (2018.01); C12Q 1/686 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/34 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/683 (2013.01); C12Q 1/6851 (2013.01); C12Q 1/686 (2013.01); C12Q 2600/156 (2013.01); C12Y 306/04013 (2013.01)] 17 Claims
 
1. A method of selecting for treatment a human subject with an autoimmune disease caused by lower levels of an RNA Helicase DDX39B, elevated levels of a soluble interleukin-7 receptor (sIL7R), or both, comprising:
obtaining a biological sample from a subject suspected of having an autoimmune disease; and
detecting or measuring in the biological sample an amount of an RNA Helicase DDX39B, the sIL7R, or both, wherein a patient is selected for treatment if they have a lower expression of DDX39B, elevated expression of sIL7R, or both; and
selecting a treatment for the subject that has increased levels of sIL7R when compared to a sample from a human subject not having an autoimmune disease having lower levels of an RNA Helicase DDX39B, elevated expression of sIL7R, or both.